LAX.SH
INDOCO REMEDIES LTD.·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
225.6
-2.55%52W Range
Market Cap
₹2,082.37 Cr
Traded: ₹2.43 Cr (0.12%) 0.0x
Free Float: ₹432.72 Cr (0.56% of FF traded)
Volume · 60D trend
1.07 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Return | -3.0% | -12.0% | -10.0% | -25.0% | -- | Stable |
| Profit | -- | -- | -- | -- | +33.0% | -- |
| Sales | +6.0% | +8.0% | +3.0% | -- | +12.0% | Stable |
| ROE | +5.0% | +5.0% | -2.0% | -- | -- | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 468 | 476 | 445 | 485 | 440 | 390 | 411 | 433 | 431 | 450 | 459 | 482 | 426 | 428 | 399 | 433 |
| Expenses | 426 | 426 | 414 | 442 | 422 | 391 | 399 | 392 | 384 | 401 | 397 | 410 | 365 | 363 | 337 | 345 |
| Operating Profit | 41 | 50 | 32 | 43 | 18 | -1 | 12 | 40 | 48 | 49 | 63 | 71 | 61 | 65 | 62 | 88 |
| Other Income | 100 | 4 | -5 | 0 | 2 | 2 | 2 | 2 | 1 | 22 | -6 | 4 | 0 | 0 | 0 | 0 |
| Interest | 28 | 46 | 26 | 25 | 26 | 18 | 16 | 18 | 14 | 12 | 10 | 8 | 8 | 9 | 7 | 5 |
| Depreciation | 35 | 32 | 32 | 32 | 30 | 29 | 29 | 29 | 28 | 26 | 24 | 21 | 20 | 18 | 17 | 16 |
| Profit Before Tax | 78 | -25 | -31 | -14 | -37 | -46 | -31 | -5 | 7 | 33 | 23 | 46 | 34 | 39 | 38 | 67 |
| Tax % | 16.0% | -5.0% | -6.0% | -32.0% | -1.0% | -9.0% | -8.0% | 107.0% | 74.0% | 33.0% | 31.0% | 24.0% | 29.0% | 34.0% | 26.0% | 26.1% |
| Net Profit | 65 | -24 | -29 | -9 | -36 | -41 | -28 | -10 | 2 | 22 | 16 | 35 | 24 | 26 | 28 | 50 |
| Exceptional Items | 97 | 4 | -6 | -1 | 0 | 0 | 1 | 0 | 0 | 20 | -8 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 7.0 | -2.3 | -3.2 | -0.9 | -3.9 | -4.4 | -2.9 | -1.0 | 0.3 | 2.5 | 1.8 | 3.8 | 2.6 | 2.8 | 3.0 | 5.4 |
| Sales Growth (YoY) | 6.4% | 22.1% | 8.3% | 12.0% | 2.1% | -13.3% | -10.5% | -10.2% | 1.2% | 5.1% | 15.0% | 11.3% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -1.7% | 7.0% | -8.3% | 10.2% | 12.8% | -5.1% | -5.1% | 0.5% | -4.2% | -2.0% | -4.8% | 13.2% | -0.5% | 7.3% | -7.9% | -- |
| OP Growth (YoY) | 127.8% | 5100.0% | 166.7% | 7.5% | -62.5% | -102.0% | -81.0% | -43.7% | -21.3% | -24.6% | 1.6% | -19.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | -18.0% | 56.3% | -25.6% | 138.9% | 1900.0% | -108.3% | -70.0% | -16.7% | -2.0% | -22.2% | -11.3% | 16.4% | -6.2% | 4.8% | -29.4% | -- |
| Profit Growth (YoY) | 46.0% | 39.0% | 13.0% | 22.0% | -1466.0% | -524.0% | -224.0% | -127.0% | -89.0% | -63.0% | -22.0% | -29.0% | -37.0% | -36.2% | -14.7% | 19.3% |
| EPS Growth (YoY) | 281.4% | 46.6% | -12.9% | 17.3% | -1485.7% | -278.1% | -261.6% | -127.3% | -89.4% | -12.1% | -42.0% | -29.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 400.9% | 27.6% | -275.6% | 77.8% | 11.4% | -53.1% | -175.0% | -471.4% | -88.6% | 39.0% | -53.5% | 43.8% | -5.4% | -8.2% | -43.5% | -- |
| OP Margin | 8.8% | 10.5% | 7.2% | 8.9% | 4.1% | -0.3% | 2.9% | 9.2% | 11.1% | 10.9% | 13.7% | 14.7% | 14.3% | 15.2% | 15.5% | 20.3% |
| Net Margin | 13.9% | -5.0% | -6.5% | -1.9% | -8.2% | -10.5% | -6.8% | -2.3% | 0.5% | 4.9% | 3.5% | 7.3% | 5.6% | 6.1% | 7.0% | 11.5% |
| Material Cost % | 33.8% | 29.6% | 27.0% | 30.0% | 30.7% | 27.2% | 27.8% | 31.6% | 32.8% | 31.3% | 31.0% | 30.6% | 30.2% | 30.7% | 32.6% | 29.4% |
| Employee Cost % | 21.7% | 23.0% | 23.8% | 21.3% | 24.3% | 27.3% | 23.8% | 21.5% | 22.5% | 19.6% | 19.6% | 19.1% | 21.5% | 17.9% | 20.6% | 18.6% |
| P/S | 1.11 | 1.24 | 1.20 | 1.08 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 369.84 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.22 | 2.44 | 2.16 | 1.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation of Earnings Conference Call on Unaudited Financial Results for Quarter and Half year ended 30th September 2026
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve A meeting of the Board of Directors ....
Attached the certificate issued by MUFG Intime India Private Ltd, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI(D & P) Regulations,2018 ....
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (LODR) Regulations,2015, please find enclosed a copy of the letter dispatched to shareholders holding shares in physical mode, ....
Intimation regarding Closure of Trading Window
Pursuant to Regulation 30 of SEBI LODR, the Committee of Executive Directors in its meeting held today i.e. 18th September, 2026 has considered and approved the incorporation of the wholly ....
Please find enclosed herewith the details of Voting Results and Scrutinizers Report for the 79th AGM of the Company held on 17th September, 2026
We are submitting herewith the details regarding the Proceedings of the 79th AGM of the Company held on Thursday, 17th September, 2026 at 10.30 am through video conferencing(VC)/other audio ....
UK MHRA inspection at Company''s manufacturing facility at Plant I (solid oral dosage form) located at Goa.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others
USFDA inspection at Company''s manufacturing facility at Plant II (Sterile) located at Goa.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi Panandikar & Others
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others
Intimation of execution of Deed of Conveyance for Sale of Company''s plot of land.
Newspaper Advertisement-Information regarding 79th Annual General meeting and E-voting
Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the financial year 2025-2026
Notice of 79th Annual General Meeting and Annual Report for the Financial year 2025-2026
Notice of 79th Annual General Meeting and Annual Report for the financial year 2025-2026
Intimation of Cut-Off Date for E voting, Book Closure and Record date for Dividend
Publication of Newspaper Advertisement- 79th Annual General Meeting to be held on 17th September, 2026 through VC/OAVM
Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026 along with Limited Review Report
Intimation of Earnings Conference Call on Unaudited Financial Results for Quarter ended 30th June, 2026
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve The Unaudited Standalone and ....
Attached the certificate issued by MUFG Intime India Private Limited, Registrar & Transfer Agent of the Company, confirming compliance under Reg 74(5) of SEBI (D&P) Regulations,2018 for ....
Intimation regarding Closure of Trading Window
Press Release : Indoco Remedies Goa Plant successfully clears Malta Medicines Authority audit
Notice for transfer of equity shares of the Company to the Investor Education and Protection Fund ("IEPF")
Indoco''s formulation plant at Baddi (Plant III) receives EU GMP Certification
Enclosed the Annual Secretarial Compliance Report dated 13-05-2026 for the Financial Year 2025-2026 issued by our Secretarial auditor CS Ajit Sathe, Proprietor of M/s. A.Y.Sathe & Co, Company ....
Intimation regarding completion of transfer of Ophthalmic Division of the Company to Sunways (India) Private Limited
The Company hereby regrets to inform about the sad demise of Dr. Anand Nadkarni (DIN : 06881461) Non Executive Director of the Company today i.e. Friday, 15th May, 2026.
Press Release:- Indoco Remedies successfully clears Malta Medicines Authority Audit
Transcript of Earnings Conference Call on Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31-03-2026
Publication of Audited Standalone & Consolidated Financial Results for the Quarter and Year ended 31-03-2026
Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended 31st March, 2026
Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors ....
Audio recording of Earnings Conference Call on Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended 31st March, 2026
Approval of Agreement to Transfer Business by Indoco Remedies Limited
Indoco Remedies announces strategic transfer of its opthalmic division to Sunways India
Intimation regarding execution of Agreement to Transfer Business with Sunways (India) Private Limited
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2026 ,inter alia, to consider and approve 1. To consider and approve ....
Intimation of ECC on Audited Financial Results for Quarter and year ended 31-03-2026
Pursuant to Regulation 30 of the SEBI (LODR)Regulations,2015, this is to inform you that the U.S. Food & Drug Administration completed Pre-approval inspection at the Company''s testing ....
Attached the certificate issued by MUFG Intime India Private Limited, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and ....
Intimation of re-appointment of Cost Auditor and Internal Auditor of the Company
Intimation regarding Closure of Trading Window
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we wish to inform you that the senior ....
Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10mg/mL
Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended 31st December, 2025.
Annual Reports
15Credit Ratings
6Concalls
31Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Jul 2024
31 Jul 2024Jun 2024
30 Jun 2024Jan 2024
31 Jan 2024Oct 2023
31 Oct 2023Jul 2023
31 Jul 2023May 2023
31 May 2023Jan 2023
31 Jan 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Jan 2020
31 Jan 2020Oct 2019
31 Oct 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Jan 2019
31 Jan 2019Nov 2018
30 Nov 2018Aug 2018
31 Aug 2018Held by ETFs
1 ETFs hold INDOCO · sorted by weight
Held by Mutual Funds
9 schemes hold INDOCO · sorted by weight